CINJ Medical - Heme Malig

Medicine & Life Sciences

1. dinaciclib 100%
2. Hodgkin Disease 58%
3. Cyclin-Dependent Kinases 46%
4. Lymphoma 38%
5. Survival 27%
6. Progression-Free Survival 27%
7. Therapeutics 26%
8. Burkitt Lymphoma 24%
9. Non-Small Cell Lung Carcinoma 23%
10. T-Cell Lymphoma 22%
11. Neoplasms 21%
12. Lymphoma, Large B-Cell, Diffuse 21%
13. Non-Hodgkin's Lymphoma 20%
14. Bispecific Antibodies 18%
15. Hereditary Hemorrhagic Telangiectasia 18%
16. B-Cell Chronic Lymphocytic Leukemia 18%
17. Brentuximab Vedotin 17%
18. Drug Therapy 14%
19. Apoptosis 14%
20. Immunotherapy 13%
21. abexinostat 13%
22. DNA Sequence Analysis 13%
23. Hematopoietic Stem Cells 12%
24. belinostat 11%
25. Canidae 11%
26. ixazomib 11%
27. Pharmacokinetics 11%
28. MK 2206 10%
29. Cyclin-Dependent Kinase 2 10%
30. Chimeric Antigen Receptors 10%
31. Clinical Studies 10%
32. andrographolide 10%
33. Andrographis 10%
34. Hematopoietic Stem Cell Transplantation 10%
35. Safety 9%
36. Aprepitant 9%
37. PCI 32765 9%
38. Mobile Health Units 9%
39. Transplants 9%
40. Cyclonic Storms 9%
41. pembrolizumab 9%
42. Ipilimumab 9%
43. Cell- and Tissue-Based Therapy 8%
44. Diterpenes 8%
45. Tumor Burden 8%
46. Bevacizumab 8%
47. Rituximab 8%
48. Lactones 8%
49. Erlotinib Hydrochloride 8%
50. Glutens 8%
51. Clinical Trials 8%
52. Community Health Services 8%
53. Cell Line 8%
54. Malignant Mesothelioma 7%
55. Transitional Cell Carcinoma 7%
56. Insurance Coverage 7%
57. Caspases 7%
58. Stem Cell Transplantation 7%
59. Radiotherapy 7%
60. Geriatrics 7%
61. Homologous Transplantation 7%
62. Precursor Cell Lymphoblastic Leukemia-Lymphoma 7%
63. Cone-Beam Computed Tomography 7%
64. Radiosurgery 7%
65. Mutation 7%
66. Tumor Lysis Syndrome 7%
67. Organ Transplantation 7%
68. Transplantation 7%
69. Graft vs Host Disease 6%
70. Reactive Oxygen Species 6%
71. Cyclin-Dependent Kinase 9 6%
72. Leukemia 6%
73. Hematologic Neoplasms 6%
74. Central Nervous System 6%
75. B-Lymphocytes 6%
76. Vaccination 6%
77. Names 6%
78. Pancreatic Neoplasms 6%
79. Natural Killer Cells 6%
80. Human Influenza 6%
81. Survival Rate 5%
82. T-Lymphocytes 5%
83. Standard of Care 5%
84. Multicenter Studies 5%
85. Hemorrhage 5%
86. Bleomycin 5%
87. Geriatric Assessment 5%
88. Multivariate Analysis 5%
89. Urinary Bladder 5%
90. Lung Neoplasms 5%
91. Doxorubicin 5%